Headquartered in Redwood City, CA Fiscal year ends December NASDAQ: ADVM adverum.com
Adverum Biotechnologies Inc is at the forefront of gene therapy, focusing on developing treatments for ocular and rare diseases. Their main project, ixoberogene soroparvovec, aims to address chronic retinal conditions like wet age-related macular degeneration and diabetic macular edema through a single injection. They're also working on a therapy for blue cone monochromacy. Originating in 2006 and based in Redwood City, California, Adverum has evolved through strategic partnerships with notable institutions and companies, emphasizing its commitment to innovative healthcare solutions.
Here are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or liquidity,…
Here are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or liquidity,…
Lee Jackson Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Ciena, CommVault Systems, Dollar General, JD.com, Kroger, Nucor, Target and Walmart.
Adverum Bio shares dropped sharply on Thursday after the firm announced data from its Optic Phase 1 clinical trial in wet age-related macular degeneration.
Chris Lange Adverum Biotechnologies shares made a handy gain on Thursday after the company announced a key update from the FDA.
Chris Lange Adverum Biotechnologies Inc is at the forefront of gene therapy, focusing on developing treatments for ocular and rare diseases. Their main project, ixoberogene soroparvovec, aims to address chronic retinal conditions like wet age-related macular degeneration and diabetic macular edema through a single injection.
The Wall Street consensus 12-month price target for ADVM is $4.88.
